Congratulations @jcstark.bsky.social and the team, antibody-lectin chimeras (AbLecs), a new modality for cancer immune therapy, now published @natbiotech.nature.com. These bispecifics can block glyco-immune checkpoint receptor ligands directly at the immune synapse/activate immune effector functions
Antibody-lectin chimeras for glyco-immune checkpoint blockade - @jcstark.bsky.social @carolynbertozzi.bskyverified.social go.nature.com/4aRDpk8
Antibody-lectin chimeras for glyco-immune checkpoint blockade - Nature Biotechnology
Cancer immunotherapy benefits from antibody-lectin chimeras that block glyco-immune checkpoints.
go.nature.com
December 16, 2025 at 4:55 PM
Congratulations @jcstark.bsky.social and the team, antibody-lectin chimeras (AbLecs), a new modality for cancer immune therapy, now published @natbiotech.nature.com. These bispecifics can block glyco-immune checkpoint receptor ligands directly at the immune synapse/activate immune effector functions
The next big thing in Triple Negative Breast Cancer:
VEGF/PD-1 Bispecifics.
Wonderful discussion by Dr. Thomas Grinda on the prospects.
Several Phase III studies planned.
@oncbrothers.bsky.social @sabcs.bsky.social @oncoalert.bsky.social
VEGF/PD-1 Bispecifics.
Wonderful discussion by Dr. Thomas Grinda on the prospects.
Several Phase III studies planned.
@oncbrothers.bsky.social @sabcs.bsky.social @oncoalert.bsky.social
December 11, 2024 at 10:25 PM
The next big thing in Triple Negative Breast Cancer:
VEGF/PD-1 Bispecifics.
Wonderful discussion by Dr. Thomas Grinda on the prospects.
Several Phase III studies planned.
@oncbrothers.bsky.social @sabcs.bsky.social @oncoalert.bsky.social
VEGF/PD-1 Bispecifics.
Wonderful discussion by Dr. Thomas Grinda on the prospects.
Several Phase III studies planned.
@oncbrothers.bsky.social @sabcs.bsky.social @oncoalert.bsky.social
February 16, 2025 at 9:47 PM
Cell Therapies/bispecifics pursuing "chasing" the next dream - Autoimmune diseases
Below - upcoming milestones
Source: Cowen
Below - upcoming milestones
Source: Cowen
November 25, 2024 at 2:31 AM
Cell Therapies/bispecifics pursuing "chasing" the next dream - Autoimmune diseases
Below - upcoming milestones
Source: Cowen
Below - upcoming milestones
Source: Cowen
Mohamad Mohty, MD, PhD, outlined areas warranting further exploration — a reproducible immune fitness score, understanding memory T-cell dynamics, & immune monitoring to predict infection risk in candidates for CAR-T/bispecifics. #IMS26
September 25, 2026 at 10:46 AM
Mohamad Mohty, MD, PhD, outlined areas warranting further exploration — a reproducible immune fitness score, understanding memory T-cell dynamics, & immune monitoring to predict infection risk in candidates for CAR-T/bispecifics. #IMS26
For readers interested in bispecific antibodies in oncology, here's a comprehensive review www.nature.com/articles/s41...
rdcu.be/eqxm5
rdcu.be/eqxm5
June 11, 2025 at 3:03 PM
For readers interested in bispecific antibodies in oncology, here's a comprehensive review www.nature.com/articles/s41...
rdcu.be/eqxm5
rdcu.be/eqxm5
Editorial highlighting a very interesting and informative article. BCMA bispecifics: breaking the chains of resistance
ashpublications.org/blood/articl...
ashpublications.org/blood/articl...
BCMA bispecifics: breaking the chains of resistance
In this issue of Blood, Lee et al1 systematically describe the mechanisms of primary resistance to BCMA×CD3 bispecific antibodies in multiple myeloma and p
ashpublications.org
December 26, 2024 at 8:56 AM
Editorial highlighting a very interesting and informative article. BCMA bispecifics: breaking the chains of resistance
ashpublications.org/blood/articl...
ashpublications.org/blood/articl...
You've heard about your ABCs, but how about your ADCs?(Antibody Drug Conjugates): Antibody therapeutics overview – monoclonals, bispecifics, ADCs, etc.
youtu.be/J_A4Q22XY3E
youtu.be/J_A4Q22XY3E
Antibody therapeutics overview – monoclonals, bispecifics, ADCs, etc.
YouTube video by the bumbling biochemist
youtu.be
March 9, 2026 at 10:54 PM
You've heard about your ABCs, but how about your ADCs?(Antibody Drug Conjugates): Antibody therapeutics overview – monoclonals, bispecifics, ADCs, etc.
youtu.be/J_A4Q22XY3E
youtu.be/J_A4Q22XY3E
During the IMS/AACR joint session, Robert Jenq, MD, spoke about the impact of commensal gut bacteria on immune modulation in the context of cancer immunotherapies, including CAR-Ts & bispecifics, & potential mechanisms. #IMS26
September 24, 2026 at 4:13 PM
During the IMS/AACR joint session, Robert Jenq, MD, spoke about the impact of commensal gut bacteria on immune modulation in the context of cancer immunotherapies, including CAR-Ts & bispecifics, & potential mechanisms. #IMS26
RRID:AB_10714831 from @thermofishersci.bsky.social was used by authors in their iScience paper. RRIDs improve reproducibility in scientific research. #methodsmatter #RRID #STMpublishing
Human lung explants as a predictive platform for evaluating the on-target, off-tumor toxicity of T cell bispecifics
Read the full paper: Human lung explants as a predictive platform for evaluating the on-target, off-tumor toxicity of T cell bispecifics
doi.org
October 2, 2026 at 7:00 AM
RRID:AB_10714831 from @thermofishersci.bsky.social was used by authors in their iScience paper. RRIDs improve reproducibility in scientific research. #methodsmatter #RRID #STMpublishing
Might do an immunology x plant biology collab between PIRL and @atinygreencell.bsky.social — has anyone expressed soluble fluorescent TCRs and/or TCR bispecifics in plants?
Any tips for making it work?
And/or any other cool plant x adaptive immune crossover ideas?
Any tips for making it work?
And/or any other cool plant x adaptive immune crossover ideas?
May 2, 2025 at 11:29 PM
Might do an immunology x plant biology collab between PIRL and @atinygreencell.bsky.social — has anyone expressed soluble fluorescent TCRs and/or TCR bispecifics in plants?
Any tips for making it work?
And/or any other cool plant x adaptive immune crossover ideas?
Any tips for making it work?
And/or any other cool plant x adaptive immune crossover ideas?
I’ve gotten so much deeper into T-cell culture, TCR sequencing, single chain trimers, TCR-T generation, &c than I ever expected to a few years ago. Now getting into TCR bispecifics, all this stuff is great.
TODO: look at more TCRs in PDB, get better at using structure prediction
TODO: look at more TCRs in PDB, get better at using structure prediction
May 8, 2025 at 1:42 AM
I’ve gotten so much deeper into T-cell culture, TCR sequencing, single chain trimers, TCR-T generation, &c than I ever expected to a few years ago. Now getting into TCR bispecifics, all this stuff is great.
TODO: look at more TCRs in PDB, get better at using structure prediction
TODO: look at more TCRs in PDB, get better at using structure prediction
Total Addressable Market For Cell Therapy/Bispecifics
November 25, 2024 at 2:35 AM
Total Addressable Market For Cell Therapy/Bispecifics
BCMA-directed bispecifics show meaningful efficacy in relapsed/refractory MM, but infection remains a risk
Read more: sohoinsider.com/meetings-con...
Read more: sohoinsider.com/meetings-con...
September 29, 2026 at 9:01 PM
BCMA-directed bispecifics show meaningful efficacy in relapsed/refractory MM, but infection remains a risk
Read more: sohoinsider.com/meetings-con...
Read more: sohoinsider.com/meetings-con...
reminds me to share a landscape peak into advanced therapies - CAR-T and bispecifics - in the autoimmune and inflammation space
July 22, 2025 at 11:57 AM
reminds me to share a landscape peak into advanced therapies - CAR-T and bispecifics - in the autoimmune and inflammation space
This took a couple of folks by surprise:
"Bispecifics overtake ADCs in China deals"
Recent BioCentury Inc. Data Graphic report from Lauren Martz dives in.
Details and analysis here: www.biocentury.com/article/6552...
"Bispecifics overtake ADCs in China deals"
Recent BioCentury Inc. Data Graphic report from Lauren Martz dives in.
Details and analysis here: www.biocentury.com/article/6552...
Bispecifics overtake ADCs in China deals
As Western biopharmas increasingly turned to Chinese biotechs to access antibody innovation in recent years, antibody-drug conjugates quickly came to domin...
www.biocentury.com
March 10, 2025 at 11:05 PM
This took a couple of folks by surprise:
"Bispecifics overtake ADCs in China deals"
Recent BioCentury Inc. Data Graphic report from Lauren Martz dives in.
Details and analysis here: www.biocentury.com/article/6552...
"Bispecifics overtake ADCs in China deals"
Recent BioCentury Inc. Data Graphic report from Lauren Martz dives in.
Details and analysis here: www.biocentury.com/article/6552...
From the UChicago Kline Lab in @bloodjournal.bsky.social: multi-omic characterization of 4 'immune quadrants' in DLBCL, with better response to bispecifics (but not CAR-T) in "GCB Hot" versus "GCB Cold." #lymsm #tcellrx https://ashpublications.org/blood/article/doi/10.1182/blood.2024025355/535294/I…
January 27, 2025 at 9:46 PM
From the UChicago Kline Lab in @bloodjournal.bsky.social: multi-omic characterization of 4 'immune quadrants' in DLBCL, with better response to bispecifics (but not CAR-T) in "GCB Hot" versus "GCB Cold." #lymsm #tcellrx https://ashpublications.org/blood/article/doi/10.1182/blood.2024025355/535294/I…
#Biden will prostate cancer diagnosis bring spotlight on masked bispecifics, radioligand, or CAR-Ts?
Once again, hopes are on the politically most vilified industry.
Once again, hopes are on the politically most vilified industry.
May 18, 2025 at 8:36 PM
#Biden will prostate cancer diagnosis bring spotlight on masked bispecifics, radioligand, or CAR-Ts?
Once again, hopes are on the politically most vilified industry.
Once again, hopes are on the politically most vilified industry.
(WO2026194744A1) discloses LILRB4×CD3 bispecifics for myeloid malignancies. HB134-074/-079 showed sub-nM LILRB4 binding vs weaker CD3 engagement (58.7–178.9 nM) and activity in a single-dose THP-1 model. Key gap: cytokines and killing vs antigen density.
October 2, 2026 at 6:45 AM
(WO2026194744A1) discloses LILRB4×CD3 bispecifics for myeloid malignancies. HB134-074/-079 showed sub-nM LILRB4 binding vs weaker CD3 engagement (58.7–178.9 nM) and activity in a single-dose THP-1 model. Key gap: cytokines and killing vs antigen density.
Designing a strong bridge to CAR-T cells with bispecifics buff.ly/w0rRc2D #hemesky
October 24, 2025 at 3:03 PM
Designing a strong bridge to CAR-T cells with bispecifics buff.ly/w0rRc2D #hemesky
Looking to be an outstanding @theaacr.bsky.social Clinical Trials Plenary session on Bispecifics and T cell engagers on Tues 4/29 10:15am CST featuring #wolchokj #hoperugo #jasonlukemd and other outstanding faculty. I am excited to be discussing CART in thyroid cancer in this great program
April 24, 2025 at 2:25 AM
Looking to be an outstanding @theaacr.bsky.social Clinical Trials Plenary session on Bispecifics and T cell engagers on Tues 4/29 10:15am CST featuring #wolchokj #hoperugo #jasonlukemd and other outstanding faculty. I am excited to be discussing CART in thyroid cancer in this great program
Good news for patients with #DLBCL Diffuse large B-cell #lymphoma that #epcoritamab has received a positive funding recommendation from the PBAC in Australia. #lymsm 2L Axi-Cel this week, bispecifics in the 3L soon, it seems. Good news on a Friday. #lymsm
Pharmaceutical Benefits Scheme (PBS) | PBAC Outcomes
See also
buff.ly
December 20, 2024 at 6:42 AM
Good news for patients with #DLBCL Diffuse large B-cell #lymphoma that #epcoritamab has received a positive funding recommendation from the PBAC in Australia. #lymsm 2L Axi-Cel this week, bispecifics in the 3L soon, it seems. Good news on a Friday. #lymsm
AbbVie has jumpstarted #JPM26 with a $650M deal with China's RemeGen in PD-1xVEGF bispecifics race.
AbbVie jumps into PD-1xVEGF bispecifics race, paying $650M upfront to China's RemeGen
AbbVie is kicking off the JP Morgan Healthcare Conference with a deal in one of oncology’s hottest fields.
endpoints.news
January 12, 2026 at 6:55 PM
AbbVie has jumpstarted #JPM26 with a $650M deal with China's RemeGen in PD-1xVEGF bispecifics race.
Haynes et al - also data on bispecifics in secondary CNS lymphoma. 5/9 showed some response. #BSH2025 @bsochaem.bsky.social
April 27, 2025 at 3:53 PM
Haynes et al - also data on bispecifics in secondary CNS lymphoma. 5/9 showed some response. #BSH2025 @bsochaem.bsky.social